Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Prolifix
Emeryville, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The Photomolecular platform uses optogenetic cell lines, illumination systems, and AI to enable up to 5-fold higher biotherapeutic titers, dynamic control of post-translational modifications, and scalable, reproducible protein production. Accepted to FDA's Emerging Technology Program for novel biomanufacturing innovation.
- Therapeutic areas
- Other
- Modalities
- AntibodyMonoclonal antibodyProteinRecombinant proteinBiologicViral vector
- Industry
- Non-Drug Biotech
02
Partnerships
Fonterra Co-operative Group (via Ki Tua Fund, strategic investor)Multiple undisclosed biopharmaceutical and nutrition companies (partnering through platform deployment)
Beyond the preview
Go deeper on Prolifix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prolifix.